14534-76-0

Usage

Occurrence

Commonly found in various fruits and vegetables

Potential Benefits

+ Antioxidant properties
+ Anti-inflammatory properties
+ Anti-cancer properties
+ Preservative in food and cosmetics
+ Ingredient in skincare products (due to potential anti-aging effects)

Research

+ Treatment for cardiovascular and neurological diseases

Industries of Application

+ Pharmaceutical
+ Cosmetic
+ Food

Upstream product

• 75-21-8 oxirane 
• 2785-97-9 (2,6-dimethoxyphenyl)lithium 
• 4670-10-4 (3,5-dimethoxyphenyl)acetic acid 
• 151-10-0 1,3-Dimethoxybenzene 

Downstream Products

• 13398-96-4 2,6-Dihydroxyphenethylalkohol 
• 16929-55-8 2-(2-Bromoethyl)-1,3-dimethoxybenzene 
• 144822-82-2 4-hydroxy-2,3-dihydrobenzofuran 

Relevant academic research and scientific papers

Method for synthesizing tasimelteon key intermediate (1R, 2R)-2-(2,3-dihydrobenzofuran-4-yl) cyclopropanemethanol

The invention discloses a method for synthesizing a tasimelteon key intermediate (1R, 2R)-2-(2,3-dihydrobenzofuran-4-yl) cyclopropanemethanol. The method comprises the following steps: 1) taking 1,3-dimethoxybenzene, tetramethylethylenediamine and a solvent, and adding ethylene oxide for reacting under the alkali effect to obtain a compound 1; 2) performing acidifying and ring-closing on the compound 1 to obtain a compound 2; 3) dissolving the compound 2 in an organic solvent, and adding trifluoromethanesulfonic anhydride under the alkali effect to obtain a compound 3; 4) dissolving ethyl acrylate or methyl acrylate and the compound 3 in the organic solvent, and reacting with a ligand under the effects of an alkali reagent and a palladium catalyst to obtain a compound 4; 5) dissolving the compound 4 in the organic solvent, and adding a reducing reagent to obtain a compound 5; 6) dissolving the compound 5 in the organic solvent, adding zinc ethide, diiodomethane and a chiral ligand, carrying out an asymmetrical Simmons-Smith reaction, thereby obtaining the product. The method disclosed by the invention can achieve the effects of reducing synthesis steps, improving the synthetic overall linear yield and reducing the cost. The structural formula is as shown in the description.

Inhibitors of α4 mediated cell adhesion

The present invention relates to a pharmaceutical composition comprising as an active ingredient a compound of formula (I), wherein Ring A is an aromatic or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene, lower alkenylene, —O-(lower alkylene)-, etc.; n is 0, 1 or 2; Z is oxygen or sulfur, W is oxygen, sulfur, —CH═CH—, —NH— or —N═CH—; R1, R2and R3are the same or different and are hydrogen, halogen, hydroxyl, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, etc.; R4is tetrazolyl, carboxyl group, amide or ester; R5is hydrogen, nitro, amino, hydroxyl, lower alkanoyl, lower alkyl etc.; R6is selected from (a) a substituted or unsubstituted phenyl group, (b) a substituted or unsubstituted pyridyl group, (c) a substituted or unsubstituted thienyl group, (d) a substituted or unsubstituted benzofuranyl group, etc.; or a pharmaceutically acceptable salt thereof.